Study wrapper · #1324
Cardiometabolic outcomes of once-weekly IcoSema in adults with type 2 diabetes: systematic review and meta-analysis of the COMBINE trials.
Editor's note
The signal readers should take from this is the weight and blood-pressure differential against insulin intensification, which is consistent with what the semaglutide component would be expected to contribute. Two caveats limit how far it travels: the HbA1c pooling carries I-squared of 98 percent, meaning the two trials disagreed sharply enough that the pooled figure is close to uninterpretable, and every cardiovascular claim rests on surrogate markers plus an explicitly illustrative modelling exercise. Only two trials met inclusion, and the authors themselves call for dedicated outcome trials before any cardiovascular benefit is regarded as established.
Plain-language abstract
IcoSema is a single weekly injection that combines a long-acting insulin with semaglutide. This analysis pooled two randomised trials (1,970 adults with type 2 diabetes) comparing it against insulin-only intensification. Blood sugar control was statistically no better than insulin alone, but weight fell by about 6 kg more, and blood pressure and cholesterol markers improved modestly. All of those are risk markers rather than actual heart events, and the authors are clear that this is a hypothesis-generating pooling of just two trials.